Home

Eli Lilly & Co. (LLY)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Eli Lilly & Co. (LLY)

Go deeper and ask any question about LLY

Company Performance

Current Price

as of Sep 13, 2024

$923.71

P/E Ratio

115.38

Market Cap

$877.92B

Description

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Metrics

Overview

  • HQIndianapolis, IN
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerLLY
  • Price$923.71-1.21%

Trading Information

  • Market Cap$877.92B
  • Float89.62%
  • Average Daily Volume (1m)2,577,656
  • Average Daily Volume (3m)3,215,033
  • EPS$8.03

Company

  • Revenue$38.92B
  • Rev Growth (1yr)35.98%
  • Net Income$2.97B
  • Gross Margin80.80%
  • EBITDA Margin41.75%
  • EBITDA$4.72B
  • EV$844.25B
  • EV/Revenue21.69
  • P/E115.38
  • P/S21.46
Documents
SEC Filings
8-K (2024-09-09)
8-K (2024-08-16)
8-K (2024-08-14)
8-K (2024-08-08)
8-K (2024-07-10)
8-K (2024-06-05)
8-K (2024-05-09)
8-K (2024-04-30)
8-K (2024-02-09)
8-K (2024-02-06)
8-K (2023-11-02)
8-K (2023-08-08)
8-K (2023-05-04)
8-K (2023-04-27)
8-K (2023-03-17)
8-K (2023-02-24)
8-K (2023-02-02)
10-Q (2024-08-08)
10-Q (2024-04-30)
10-Q (2023-11-02)
10-Q (2023-08-08)
10-Q (2023-04-27)
10-K (2024-02-21)
10-K (2023-02-22)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-02)
Earnings Report (2023-08-08)
Factset Street Account
UK MHRA authorises Lilly's Mounjaro (tirzepatide) for weight management and weight loss in adults aged 18 and over ($620.78, +20.85) (2023-11-08T20:40:48Z)
StreetAccount Metrics Recap - Eli Lilly Q3 Earnings ($554.46, 0.00) (2023-11-02T10:41:31Z)
StreetAccount Earnings Call Q&A Summary: Eli Lilly Q3 ($577.36, +22.90) (2023-11-02T16:16:46Z)
StreetAccount Consensus Metrics Preview - Eli Lilly Q3 Earnings ($565.44, +5.21) (2023-10-30T15:48:53Z)
Street Takeaways - Eli Lilly Q3 Earnings ($586.74, +18.93) (2023-11-06T16:10:26Z)
Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases ($553.93, 0.00) (2023-11-01T07:30:06Z)
Results of phase 1 trial of Eli Lilly's lepodisiran published in JAMA ($597.71, 0.00) (2023-11-22T02:19:00Z)
PRISM BioLab announces license and collaboration agreement with Lilly on discovery of small molecule inhibitors of protein-protein interaction targets ($592.02, +0.49) (2023-11-28T20:11:15Z)
NICE recommends Lilly's Omvoh to treat moderately to severely active ulcerative colitis ($592.43, 0.00) (2023-10-25T04:32:02Z)
NICE recommends Lilly's Mounjaro to treat type 2 diabetes ($592.43, 0.00) (2023-10-25T04:36:04Z)
Mablink Bioscience announces agreement to be acquired by Eli Lilly; terms undisclosed ($604.92, -3.39) (2023-10-18T18:58:12Z)
Lilly's OMVOH (MIRIKIZUMAB) now available in Canada - for adults with moderately to severely active ulcerative colitis ($616.64, 0.00) (2023-10-17T13:04:00Z)
Lilly's announced that mirikizumab met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy for the treatment of adults with Crohn's disease ($605.28, 0.00) (2023-10-12T10:49:01Z)
Lilly to expand injectable manufacturing capacity with planned $2.5B site in Germany ($588.75, 0.00) (2023-11-17T13:03:56Z)
FDA Approves Eli Lilly's Omvoh (mirikizumab-mrkz) infusion for treatment of moderately to severely active ulcerative colitis in adults ($568.10, 0.00) (2023-10-27T11:48:27Z)
EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Eli Lilly's Mounjaro ($591.32, 0.00) (2023-11-10T13:09:36Z)
Eli Lilly's Mounjaro now available in Canada ($577.25, +22.79) (2023-11-02T19:45:03Z)
Eli Lilly to announce "single-digit billion" investment in new plant in Germany -- Reuters citing sources ($589.08, -21.74) (2023-11-15T19:11:27Z)
Eli Lilly reports Q3 non-GAAP EPS $0.10 vs year-ago $1.98; FactSet ($0.18) [10 est, ($0.90)-0.35] ($554.46, 0.00) (2023-11-02T10:35:01Z)
Eli Lilly announces Jaypirca approved by FDA for treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor ($584.04, 0.00) (2023-12-01T22:38:21Z)
Wikipedia
Eli_Lilly_&_Co.